Creating a new vaccine to treat prostate cancer
Official title: Development of a Therapeutic SAPNANO-ESO Vaccine for Prostate Cancer
Funded at Immunova Therapeutics, LLC · NIH-10662536 · Data updated 2026-11-12
This study is testing a new type of vaccine that could help fight prostate cancer in patients with specific tumors, aiming to boost the body's immune response without needing special cells, and it hopes to improve treatment results based on encouraging early findings in mice.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immunova Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Monrovia, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44CA275489-02 |
| Project ID | NIH-10662536 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with prostate cancer who have tumors expressing the NY-ESO-1 antigen.
✕Less likely to help
Patients with prostate cancer that do not express the NY-ESO-1 antigen may not benefit from this vaccine.
What this research studies
This research focuses on developing a novel vaccine technology called self-assembled peptide nanoparticles (SAPNANO) to treat prostate cancer, particularly in patients with NY-ESO-1 positive tumors. The vaccine aims to induce strong immune responses against prostate cancer cells without the need for dendritic cells, which are typically used in other immunotherapy approaches. By delivering the vaccine intravenously, the goal is to enhance the body's ability to fight cancer and potentially eliminate tumor cells. The research is based on promising results from mouse models, indicating that this vaccine could significantly improve treatment outcomes for prostate cancer patients.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with prostate cancer, potentially improving survival rates and quality of life.
How similar studies have gone: While immunotherapy has shown promise in other cancers, this specific approach using SAPNANO technology is novel and has not been widely tested in prostate cancer.
Where this research is happening
-
Immunova Therapeutics, LLC
Monrovia, United States Active
Researchers
- Principal investigator: Wang, Yicheng — Immunova Therapeutics, LLC
- Study coordinator: Wang, Yicheng
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.